Effects of tamoxifen on endometrial carcinogenesis in mice

Japanese Journal of Cancer Research

Volumn 89, Issue 5, 1998, Pages 502-509

  Niwa, Kenji ^a   Morishita, Shigeo ^a   Hashimoto, Midori ^a   Itoh, Tsuneo ^a   Fujimoto, Jiro ^a   Mori, Hideki ^a   Tamaya, Teruhiko ^a  

^a GIFU UNIVERSITY   (Japan)

Author keywords

Endometrial carcinogenesis; Fos Jun; Mice; Polymerase chain reaction; Tamoxifen

Indexed keywords

TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INCIDENCE; CARCINOGENESIS; CONTROLLED STUDY; DIET; ENDOMETRIUM; ENDOMETRIUM CANCER; FEMALE; NONHUMAN; ORAL DRUG ADMINISTRATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RAT; UTERINE TUBE;

EID: 0031838115     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.1998.tb03290.x     Document Type: Article

References (38)

1. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet, 339, 1-15 (1992).
2. Powles, T. J. The case for clinical trials of tamoxifen for prevention of breast cancer. Lancet, 340, 1145-1147 (1992).
3. Stone, R. NIH fends off critics of tamoxifen study. Science, 258, 734 (1992).
4. Jordan, V. C. Antitumor activity of antiestrogen ICI 46,474 (tamoxifen) in dimethylbenzanthracene (DMBA)-induced rat mammary carcinoma model. J. Steroid Biochem., 4, 354 (1974).
5. Lippman, M., Bolan, G. and Huff, K. Interactions of antiestrogen with human breast cancer in long-term tissue culture. Cancer Treat. Rep., 60, 1421-1429 (1976).
6. Lahti, E., Vuopala, S., Kauppila, A., Blanco, G., Ruokonen, A. and Laatikainen, T. Maturation of vaginal and endometrial epithelium in postmenopausal breast cancer patients receiving long-term tamoxifen. Gynecol. Oncol., 55, 410-414 (1994).
7. Neven, P., De Muylder, X., Van Belle, Y., Vunderick, G. and De Muylder, E. Hysteroscopic follow-up during tamoxifen treatment. Eur. J. Obstet. Gynecol. Reprod. Biol., 35, 235-238 (1990).
8. De Muylder, X., Neven, P., De Somer, M., Van Belle, Y., Vanderick, G. and De Muylder, E. Endometrial lesions in patients undergoing tamoxifen therapy. Int. J. Gynecol. Obstet., 36, 127-130 (1991).
9. Lahti, E., Blanco, G., Kauppila, A., Apaja-Sarkkinen, M., Taskinen, P. and Laatikainen, T. Endometrial changes in postmenopausal breast cancer patients receiving long-term tamoxifen. Obstet. Gynecol., 81, 660-664 (1993).
10. Le Bouedec, G. and Dauplat, J. Cancer of endometrium caused by antiestrogens. Rev. Fr. Gynecol. Obstet., 87, 345-348 (1992).
11. Fornander, T., Rutqvist, L. E., Cedermark, B., Glas, U., Mattson, A., Silfverswärd, C., Skoog, L., Somell, A., Theve, T., Wilking, N., Askergren, J. and Hjalmar, M. L. Adjuvant tamoxifen in early breast cancer. Occurrence of new primary cancers. Lancet, i, 117-119 (1989).
12. Williams, G. M., Iatropoulos, M. J., Djordjevic, M. V. and Kaltenberg, O. P. The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis, 14, 315-317 (1993).
13. Sakakibara, K., Kan, N. C. and Satyaswaroop, P. G. Both 17β-estradiol and tamoxifen induce c-fos messenger ribonucleic acid expression in human endometrial carcinoma in nude mice. Am. J. Obstet. Gynecol., 166, 206-212 (1992).
14. Niwa, K., Murase, T., Furui, T., Morishita, S., Mori, H., Tanaka, T., Mori, H. and Tamaya, T. Enhancing effects of estrogens on endometrial carcinogenesis initiated by N-methyl-N-nitrosourea in ICR mice. Jpn. J. Cancer Res., 84, 951-955 (1993).
15. Chomczynski, P. and Sacchi, N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem., 162, 156-159 (1987).
16. Van Beveren, C., Van Straaten, F., Curran, T., Müller, R. and Verma, I. M. Analysis of FBJ-MuSV provirus and c-fos (mouse) gene reveals that viral and cellular fos gene products have different carboxy termini. Cell, 32, 1241-1255 (1983).
17. Lamph, W. W., Wamsley, P., Sassone-Corsi, P. and Verma, I. M. Induction of protooncogene jun/AP-1 by serum and TPA. Nature, 334, 629-631 (1988).
18. Sabath, D., Broome, H. E. and Prystowsky, M. B. mRNA is a major interleukin 2-induced transcript in a cloned T-helper lymphocyte. Gene, 91, 185-191 (1990).
19. Scully, R. E., Bonfiglio, T. A., Kurman, R. J., Silverberg, S. G. and Wilkinson, E. J. Histological classification of tumours of the female genital tract. In "Histological Typing of Female Genital Tract Tumours," 2nd Ed., pp. 13-18 (1994). WHO, Geneva.
20. Muñoz, N., Dunn, T.B. and Turusov, V. S. Tumours of the vagina and uterus. In "Pathology of Tumours in Laboratory Animals. Vol. II. Tumours of the Mouse," ed. V. S. Turusov, pp. 359-383 (1979). IARC, Lyon.
21. Newbold, R. R., Jefferson, W. N., Padilla-Burgos, E. and Bullock, B. C. Uterine carcinoma in mice treated neonatally with Tamoxifen. Carcinogmesis, 18, 2293-2298 (1997).
22. Adamson, E.D. Oncogenes in development. Development, 99, 449-471 (1987).
23. Weitz, A. and Bresciani, F. Estrogen induces expression of c-fos and c-myc protooncogenes in the rat uterus. Mol. Endocrinol., 2, 816-824 (1988).
24. Weitz, A., Cicatiello, L., Persiot, E., Scalona, M. and Bresciani, F. Estrogen stimulation of transcription of c-jun protooncogene. Mol. Endocrinol., 4, 1031-1050 (1990).
25. Morishita, S., Niwa, K., Ichigo, S., Hori, M., Murase, T., Fujimoto, J. and Tamaya, T. Overexpressions of c-fos/jun mRNA and their oncoproteins (Fos/Jun) in the mouse uterus treated with three natural estrogens. Cancer Lett., 97, 225-231 (1995).
26. Kruijer, W., Cooper, J. A., Hunter, T. and Verma, I. M. Platelet-derived growth factor induces rapid but transient expression of c-fos gene and protein. Nature, 312, 711-716 (1984).
27. Müller, R., Bravo, R. and Bruckhardt, J. Induction of c-fos gene and protein by growth factors precedes activation of c-myc. Nature. 312, 716-721 (1984).
28. Curren, T. and Mogan, J. I. Superinduction of c-fos by nerve growth factor in the presence of peripherally active benzodiapines. Science, 229, 1265-1268 (1986).
29. Müller, R., Verma, I. M. and Adamson, E. D. Expression of c-oncogenes: c-fos observed in mouse and human tissues using an antibody to a synthetic peptide. EMBO J., 4, 941-947 (1985).
30. Turner, R. and Tjian, R. Leucine repeats and adjacent DNA binding domain mediate the formation of functional c-Fos-c-Jun heterodimer. Science, 243, 1689-1697 (1989).
31. Bohmman, D., Admon, A., Turner, D. R. and Tjian, R. Transcriptional regulation by AP-1 family of enhancer binding proteins: a nuclear target for signal transduction. Cold Spring Harbor Symp. Quant. Biol., 53, 695-700 (1989).
32. Nephew, K. P., Polek, T. C., Akcali, K. C. and Khan, S. A. The antiestrogen tamoxifen induces c-fos and Jun-B, but not c-jun or jun-D, protooncogenes in the rat uterus. Endocrinology, 133, 419-422 (1993).
33. Vancutsem, P. M., Lazarus, P. and Williams, G. M. Frequent and specific mutations of the rat p53 gene in hepatocarcinomas induced by tamoxifen. Cancer Res., 54, 3864-3867 (1994).
34. Murase, T., Niwa, K., Morishita, S., Itoh, N., Mori, H., Tanaka, T. and Tamaya, T. Rare occurrence of p53 and ras gene mutations in preneoplastic and neoplastic mouse endometrial lesions induced by N-methyl-N-nitrosourea and I7β-estradiol. Cancer Lett., 97, 223-227 (1995).
35. White, I. N. H., de Matteis, F., Davies, A., Smith, L. L., Crotton-Sleigh, C., Venitt, S., Hewer, A. and Phillips, D. H. Genotoxic potential of tamoxifen and analogues in female Fischer F344/N rats, DBA/2 and C57B1/6 mice and human MCL-5 cells. Carcinogenesis (Lond.), 13, 2197-2203 (1992).
36. Greaves, P., Goonetilleke, R., Nunn, G., Topham, J. and Orton, T. Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Res., 53, 3919-3924 (1993).
37. Hard, G. C. Atropoulos, M. J., Jordan, K., Radi, L., Kaltenberg, O. P., Imondi, A. R. and Williams, G. M. Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD(BR) rats. Cancer Res., 53, 4534-4541 (1993).
38. Niwa, K., Tanaka, K., Mori, H., Yokoyama, Y., Furui, T., Mori, H. and Tamaya, T. Rapid induction of endometrial carcinoma in ICR mice treated with N-methyl-N-nitrosourea and I7β-estradiol. Jpn. J. Cancer Res., 82, 1391-1396 (1991).